For all enrolling trials, patients must have signed Informed Consent before beginning treatment. 

Breast

 Regeneron

• Cemiplimab Survivorship Edidemiology Study
• Describe the long term real-world use and effectiveness of cemiplimab for Cutaneous Squamous Cell Carcinoma
• Patients in this study will include men and women ≥18 years of age who have recently initiated or are planning to initiate treatment with commercially available cemiplimab for CSCC in a real-world setting.

  Solid Tumor

Multiple Myeloma

• Relapsed MM
• Measurable disease w/ at least 1 of the following:
• Immunoglobulin G (IgG) MM: serum monoclonal protein (M-protein) level ≥ 1.0 g/dL
• IgA, IgD, IgE multiple myeloma: serum M-protein level ≥ 0.5 g/dL
• urine M-protein ≥ 200 mg per 24 hours in subjects without detectable serum or urine M-protein, serum-free light chain (SFLC) ≥ 100  mg(involved light chain), and an abnormal serum kappa lambda ratio.

Multiple Myeloma

Febrile Neutropenia – (On Hold)

Cutaneous Squamous Cell Carcinoma

Non-Small Cell Lung

For Enrollment or More Information, contact clinical trials research coordinator Joe Howe. 704-247-9179, x201.